Galantamine Tablet, Film Coated
Product Images NDC 68084-729

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 68084-729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp72921

Galantamine 4 mg film-coated tablet shown with a round, white shape. One side is embossed with the letter 'F' and the other side with the number '49'. This oral human prescription drug is labeled by American Health Packaging.*

FDA Label Image

Figure 1

Line graph showing the mean change from baseline in ADAS-cog score over 21 weeks of treatment. The y-axis represents mean change with improvement upward and decline downward. Four lines depict results for Placebo, 8 mg/day, 16 mg/day, and 24 mg/day dosing groups, showing trends of cognitive performance over time.*

FDA Label Image

Figure 10

A line graph depicting the mean change from baseline in ADAS-cog score over weeks of treatment. The x-axis represents weeks of treatment (0, 4, 13), and the y-axis represents mean change with improvement indicated upward and decline downward. Two groups are shown: placebo (open circles) and 24 or 32 mg/day (solid diamonds). The 24 or 32 mg/day group shows improvement over time, while placebo remains near baseline or declines slightly.*

FDA Label Image

Figure 11

A cumulative percentage of patients graph comparing ADAS-cog change from baseline between placebo and 24 or 32 mg/day treatment groups. The x-axis shows change from baseline on the ADAS-cog scale, ranging from -15 to 15, with markers at -10, -7, -4, and 0 points. The y-axis represents cumulative percentage of patients from 0 to 100%. The graph visually differentiates data points for placebo (circles) and treatment group (diamonds).*

FDA Label Image

Figure 12

A bar chart displaying the percentage of patients by CIBIC-plus Rating categories comparing Placebo and 24 or 32 mg/day dosage groups of Galantamine. Categories range from Markedly Improved to Markedly Worse, with the highest percentages in the No Change and Minimally Improved groups.*

FDA Label Image

Figure 2

A line graph showing the cumulative percentage of patients versus ADAS-cog change from baseline for placebo and three dosage groups of galantamine (8 mg/day, 16 mg/day, 24 mg/day). The graph compares cognitive change outcomes across the different treatment groups with reference lines indicating points of change.*

FDA Label Image

Figure 3

A bar chart showing patient percentage distribution across CIBIC-plus rating categories for placebo and galantamine doses (8, 16, 24 mg/day). The x-axis lists categories from Markedly Improved to Markedly Worse. The y-axis shows the percentage of patients. The chart compares the effects of different dosages of galantamine and placebo on patient condition.*

FDA Label Image

Figure 4

A line chart showing mean change from baseline in ADAS-cog scores over 26 weeks of treatment with placebo, 24 mg/day, and 32 mg/day doses of galantamine. The x-axis represents weeks of treatment (0, 3, 13, and 26), and the y-axis shows the change from baseline with improvement upward and decline downward. The chart includes error bars for standard error of the mean.*

FDA Label Image

Figure 5

A cumulative percentage of patients line graph showing ADAS-cog change from baseline on the x-axis and cumulative percentage on the y-axis. It compares placebo, 24 mg/day, and 32 mg/day treatment groups by different markers and shows vertical lines marking -10, -7, -4 points change and no change at 0 on the x-axis.*

FDA Label Image

Figure 6

A bar chart showing the distribution of patient outcomes by CIBIC-plus Rating categories (Markedly Improved to Markedly Worse) comparing Placebo, 24 mg/day, and 32 mg/day treatment groups. The y-axis represents the percentage of patients, illustrating differences in response rates among the groups.*

FDA Label Image

Figure 7

A line graph showing mean change from baseline in ADAS-cog score over 26 weeks of treatment for placebo, 24 mg/day, and 32 mg/day groups. The vertical axis measures change in ADAS-cog score with improvement indicated upward and decline downward. The horizontal axis represents treatment duration in weeks. The 24 mg/day and 32 mg/day groups show improvement over time, while the placebo group shows decline.*

FDA Label Image

Figure 8

This chart depicts the cumulative percentage of patients plotted against the ADAS-cog change from baseline, comparing placebo, 24 mg/day, and 32 mg/day doses of Galantamine. The graph includes vertical reference lines for changes of -10, -7, -4 points, and no change, illustrating cognitive changes across treatment groups.*

FDA Label Image

Figure 9

A bar chart showing the distribution of patients' outcomes on the CIBIC-plus rating scale for placebo, 24 mg/day, and 32 mg/day treatment groups. The vertical axis represents the percentage of patients, while the horizontal axis lists categories from markedly improved to markedly worse. The chart compares patient responses across three treatment groups.*

FDA Label Image

Structure

Chemical structure of galantamine hydrobromide, showing its multi-ring molecular framework with specific stereochemistry and functional groups, including a methoxy group and a nitrogen-containing ring.*

FDA Label Image

Galantamine Hydrobromide Structural Formula (Image 01)

Label for Galantamine 4 mg film-coated oral tablets, USP. The package contains 30 tablets (3 blister packs of 10). Distributed by American Health Packaging, Columbus, Ohio. Includes barcode, storage instructions, and safety warnings. NDC 68084-729.*

FDA Label Image

Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Image 02)

Galantamine 4 mg film-coated tablets packaging labels by American Health Packaging. Each label includes the product name, strength, dosage form, NDC barcode, lot number, and expiry date fields. The label also mentions the manufacturer location: Columbus, Ohio 43217.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.